OZON TERAPİ ALAN HASTALARDA TEDAVİ ÖNCESİ VE SONRASI Jugular Venöz Oksimetri (SjvO2) ve NONINVAZIV SANTRAL VENÖZ BASINÇ (CVP ) DEĞERLERİNİN KARŞILAŞTIRILMASI
Abstract
Tıpta kullanılan 3 oksijen atomu içeren ozon ve oksijenden oluşan gaz karışımı, vücut sıvılarına ve boşluklara uygulandığında bu terapötik yöntem, tıbbi ozon tedavisi olarak bilinir. Ozon tedavisinin Santral Juguler Venöz sistemde ki etkinliği bu çalışmada noninvaziv SjvO2 ölçümleri ile takip edilmesi amaçlanmıştır.
Keywords
References
- Referans 1 Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen/ozone in rabbit. Int J Med Biol Environ. 2000;28:109–13.
- Referans 2 Borrelli, E.; Bocci, V. Visual improvement following ozonetherapy in dry age related macular degeneration; a review. Med. Hypothesis Discov. Innov. Ophthalmol. 2013, 2, 47–51.
Comparison of Jugular Venous Oximetry (SjvO2) and NONINVASIVE CENTRAL VENOUS PRESSURE (CVP) IN PATIENTS WITH OZONE THERAPY BEFORE AND AFTER TREATMENT
Abstract
This therapeutic method is known as medical ozone therapy when the gas mixture consisting of ozone and oxygen, which is used in medicine, containing 3 oxygen atoms, is applied to body fluids and cavities. In this study, it was aimed to monitor the effectiveness of ozone therapy in the Central Jugular Venous system with noninvasive SjvO2 measurements.
Keywords
References
- Referans 1 Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen/ozone in rabbit. Int J Med Biol Environ. 2000;28:109–13.
- Referans 2 Borrelli, E.; Bocci, V. Visual improvement following ozonetherapy in dry age related macular degeneration; a review. Med. Hypothesis Discov. Innov. Ophthalmol. 2013, 2, 47–51.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Articles |
| Authors | |
| Publication Date | October 13, 2021 |
| Submission Date | April 26, 2021 |
| Acceptance Date | June 10, 2021 |
| Published in Issue | Year 2021 Volume: 7 Issue: 3 |
All site content, except where otherwise noted, is licensed under a Creative Common Attribution Licence. (CC-BY-NC 4.0)